Graham Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Graham Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,302	Closed	-$234K	–	1146
2025 Q4	$234K	Sell	9,302 -13,894	-60%	-$326K	0.01%	972
2025 Q3	$525K	Sell	23,196 -19,895	-46%	-$464K	0.01%	591
2025 Q2	$746K	Buy	43,091 +14,955	+53%	+$277K	0.01%	677
2025 Q1	$615K	Buy	+28,136	New	+$777K	0.01%	724
2024 Q4	–	Sell	-16,873	Closed	-$487K	–	1220
2024 Q3	$487K	Buy	16,873 +11,636	+222%	+$431K	0.01%	645
2024 Q2	$201K	Sell	5,237 -1,505	-22%	-$68.2K	﹤0.01%	866
2024 Q1	$396K	Buy	+6,742	New	+$430K	0.01%	688
2022 Q3	–	Sell	-40,720	Closed	-$1.84M	–	1052
2022 Q2	$1.84M	Buy	40,720 +5,690	+16%	+$259K	0.07%	229
2022 Q1	$1.78M	Buy	+35,030	New	+$1.55M	0.06%	152

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Graham Capital Management's APLS Position: Q1 2026 in Review

Graham Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 9,302 shares — an estimated $234K sold.

Graham Capital Management first reported a position in APLS in Q1 2022 and held it in 9 quarters. The position peaked at $1.84M in Q2 2022. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Graham Capital Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Graham Capital Management sold 9,302 Apellis Pharmaceuticals shares in Q1 2026, an estimated $234K.
Graham Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 9 quarters.
Graham Capital Management's Apellis Pharmaceuticals position peaked at $1.84M in Q2 2022.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.